CIP2A and non-small cell lung carcinoma: Combination treatment therapy of SMAPs and second-generation EGFR-TKI, Afatinib, resulted in degradation of CIP2A via the P13K pathway in EGFR-TKI-resistant human NSCLC cell lines [188].